Doctor of medical sciences. Specialist in the field of nuclear medicine and radiology. Professor at the University of Warmia and Mazury in Olsztyn. Member of many organizations such as the Polish Network for Neuroendocrine Tumors, the American Society of Nuclear Medicine and Molecular Imaging (SNMMI), European Association of Nuclear Medicine, and the Polish Society of Nuclear Medicine.
The manager and main contractor of many research projects and sponsored own. He was awarded the distinction of the Polish Medical Association.
Science publications
Author and co-author of numerous scientific papers. His output consists of over 100 scientific works. He is also the author of over 200 papers and congress reports, which are presented at scientific meetings in Poland and abroad.
Clinical Interests
- Clinical diagnostics, imaging and biochemical neuroendocrine tumors in certain genetic syndromes like PGL (mutations SDHx), MEN1, men2, VHL, NF1 and others;
- The use of SST receprots’ antagonists in the diagnosis and therapy of patients with neuroendocrine tumors;
- Other methods of treatment including the treatment of high-molecular and chemical form of various types of neuroendocrine tumors (NEN);
- Treatment and conducting clinical patients with advanced NEN, using somatostatin analogues, drugs molecular chemotherapy and other therapies local (loco-regional) using ablative techniques, radioembolizacji (90Y SIRT) and brachytherapy 192Ir HDR (High Dose Rate) under control computed tomography (CT);
- Radioisotope treatment intravenous and intra-arterial patients with advanced, unresective NEN figure using radioisotope-labeled somatostatin analogues (90 Y and 177 Lu DOTATATE / TOC, etc.) as a peptide radionuclide therapy (PRRT – Peptide Receptor Radionuclide Therapy);
- Broadly diagnostic and clinical imaging of neuroendocrine tumors (NEN) using CT, MR, and functional testing, scintigraphy: somatostatin receptor scintigraphy (SRS), 123I mIBG, PET 68Ga DOTATATE / TOC, 18F DOPA, FDG PET, etc.
- Molecular diagnostics based on the analysis of gene transcripts in peripheral blood (NETest) of various forms of neuroendocrine tumors, with the assessment of disease activity and assessment of the effectiveness of different forms of treatment of advanced NEN.
- Embolization and radioembolization of primary and metastatic liver tumors using spheres labeled with yttrium (90Y SIRT, Sirsphers; Sirtex Ltd, Australia) and the Rhine (188 Re HSA microspheres), a pioneer in the introduction of these therapies in Poland.
- The use of diagnostic imaging, in particular MRI (DWI and a ADC mapping technique) in the evaluation of the effectiveness of various therapies for advanced cancer, in particular neuroendocrine tumors, HCC, metastatic colorectal cancer and other primary and metastatic liver tumor.
- HDR brachytherapy 192Ir – (High Dose Rate) under the control of computed tomography (CT) in patients with advanced primary and secondary unresective malignancies of liver.
Radiosynoviorthesis (RSO) for patients with exudative chronic inflammatory arthritis of various etiologies, including any joints of children and adults, including hemophiliacs; - Radionuclide Diagnostics (sestaMIBI, Tetrofosmin, FDG) in patients with breast cancer. Assessment of primary lesions, recurrence of the cancer, as well as the evaluation of response to treatment with cytotoxic and hormonal therapies in patients with breast cancer;
- The use of SPECT and PET techniques and reconstruction algorithms for image reconstruction in the wider diagnostic imaging using radioisotopes;